Repetitive transcranial magnetic stimulation (rTMS) is a commonly- used treatment for major depressive disorder (MDD). However, our understanding of the mechanism by which TMS exerts its antidepressant effect is minimal. Furthermore, we lack brain signals that can be used to predict and track clinical outcome. Such signals would allow for treatment stratification and optimization. Here, we performed a randomized, sham-controlled clinical trial and measured electrophysiological, neuroimaging, and clinical changes before and after rTMS. Patients (N = 36) were randomized to receive either active or sham rTMS to the left dorsolateral prefrontal cortex (dlPFC) for 20 consecutive weekdays. To capture the rTMS-driven changes in connectivity and causal excitability, resting fMRI and TMS/EEG were performed before and after the treatment. Baseline causal connectivity differences between depressed patients and healthy controls were also evaluated with concurrent TMS/fMRI. We found that active, but not sham rTMS elicited (1) an increase in dlPFC global connectivity, (2) induction of negative dlPFC-amygdala connectivity, and (3) local and distributed changes in TMS/EEG potentials. Global connectivity changes predicted clinical outcome, while both global connectivity and TMS/EEG changes tracked clinical outcome. In patients but not healthy participants, we observed a perturbed inhibitory effect of the dlPFC on the amygdala. Taken together, rTMS induced lasting connectivity and excitability changes from the site of stimulation, such that after active treatment, the dlPFC appeared better able to engage in top-down control of the amygdala. These measures of network functioning both predicted and tracked clinical outcome, potentially opening the door to treatment optimization.
Depression is a highly prevalent and serious mental illness, with unsatisfying treatment success rates for even the best-calibrated combinations of pharmacotherapy and psychotherapy [1, 2]. Newer treatments such as repetitive transcranial magnetic stimulation (rTMS) may modulate connectivity in and between specific brain networks , and may thus enable development of non-invasive therapies that build on our emerging understanding of brain network dysfunction in depression. Clinical trials have demonstrated 10 Hz rTMS to the dorsolateral prefrontal cortex (dlPFC) to have sham-controlled evidence for antidepressant efficacy [4, 5], resulting in Food and Drug Administration clearance and subsequent broad clinical adoption. Even so, remission rates have been disappointingly low [6, 7]. Moreover, despite evidence of its clinical utility, rTMS was developed without a specific neurophysiological process to modify or a clear sense of its specific anatomical target within the dlPFC, a region we now understand to be highly diverse . Recently, several studies have attempted to resolve this heterogeneity as it relates to rTMS by using task functional magnetic resonance imaging (fMRI) , individualized brain network mapping , and resting-state connectivity  (for a review see ref. ). While promising, prior studies typically: (1) lack a sham control arm necessary to distinguish intervention effects from factors like placebo responses, and (2) aside from changes in connectivity, fail to use causal brain measurements (e.g., activation in one region causes brain changes in another region) to explain the mechanism underlying rTMS. Optimization of the treatment technique has thus been hindered by our poor mechanistic understanding of the antidepressant effect of rTMS, and the lack of neural circuit signals that predict and track clinical outcome.
To date, neuroimaging work investigating left dlPFC rTMS in depression has used conventional brain measurement (e.g., fMRI or electroencephalography (EEG)) before and after a treatment course (for a review see ref. ). These studies generally suggest a change in either frontal or temporal lobe function, activity, or connectivity after rTMS (often also tied to successful clinical outcome) [3, 13]. Regarding frontal lobe changes, rTMS has been shown to normalize within-network DMN hyperconnectivity , normalize abnormal dlPFC-medial prefrontal connectivity , and predict outcome based on dlPFC-anterior cingulate [9, 15] or anterior cingulate–parietal connectivity . Regarding temporal lobe changes, left dlPFC rTMS has been shown to increase amygdala blood flow  and decrease responses to negative faces .
In addition to which neuroanatomical targets are relevant for the antidepressant effect of rTMS, a mechanistic understanding of how rTMS exerts its effect on these regions is limited. There is a long-standing notion that 10 Hz rTMS works by increasing net excitability through a long-term potentiation-like (LTP) phenomenon. However, limited evidence exists in humans to support this claim. In fact, recent animal work on rTMS itself (rather than electrically -induced LTP in brain slices) suggests a different mechanism than excitatory LTP: decreased intracortical inhibition. For example, 10 Hz rTMS applied to cat visual cortex resulted in a decrease in the prolonged inhibitory rebound to single TMS pulses, along with evidence of decreased inhibition during visual processing . We also recently demonstrated that a 10-minute application of intracranial electrical cortical stimulation in an rTMS-like 10 Hz fashion suppressed the 20–40 ms stimulation-evoked potential . Given that this potential is thought to be inhibitory in nature [20, 21], these studies suggest that rTMS may elicit changes through a previously unconsidered mechanism of decreased cortical inhibition. One way to understand which regions and neurophysiological processes are altered by rTMS non-invasively is therefore to examine brain activity directly induced by TMS pulses using concurrent fMRI or EEG [22,23,24]. Concurrent TMS/fMRI can likewise reveal which downstream brain regions are influenced by dlPFC stimulation .
To better understand the mechanisms and predictors of 10 Hz rTMS treatment, we conducted a multimodal randomized sham-controlled rTMS study in patients with major depression, and examined changes in resting-state fMRI connectivity (Fig. 2) and TMS/EEG-induced neural responses (Figs. 3 and 4). Additionally, we compared TMS-evoked responses using concurrent TMS/fMRI in patients and controls prior to treatment to determine whether rTMS-induced connectivity changes reflected causally disrupted neural relationships in depression (Fig. 5). Our initial pre-specified hypotheses on ClinicalTrials.gov (NCT01829165) focused exclusively on concurrent TMS/fMRI; however, equipment failure precluded us from collecting these data for 1.5 years, which included all planned post-treatment measurements. Thus, we were forced to revise the analysis in favor of resting fMRI and TMS/EEG. The overall goals, however, remained the same, including (1) to examine the causal interactions between the dlPFC and other brain regions implicated in depression, and (2) to examine the impact of antidepressant rTMS treatment on these connectivity abnormalities. We hypothesized that 10 Hz left dlPFC rTMS induces connectivity changes specific to the stimulated site in dlPFC, that these changes would be reflected in adjustment of abnormal resting fMRI and TMS/EEG patterns, and that the strength of these effects would predict and track clinical outcome. Together, our results suggest that 10 Hz dlPFC rTMS in depression induces long-lasting, clinically relevant neuromodulatory effects, likely related in part to a strengthening of top-down control from dlPFC to the amygdala.
Materials and methods
The study methods are presented here in brief, with additional detail available in the Supplemental Methods section in the online data supplement. Of note, our study differs from what was pre-registered on ClinicalTrials.gov (NCT01829165), because the pre-specified hypotheses relied on concurrent TMS/fMRI data, which we could not gather post-treatment due to equipment failure. The following analysis was designed to take advantage of the multimodal data we were able to collect despite this equipment failure.
Participants, assessments, and inclusion criteria
Eighty-five patients with major depressive disorder were assessed for eligibility (see clinicaltrials.gov registration: NCT01829165 and Fig. S1 for CONSORT diagram). After exclusion based on the criteria outlined below, or dropout prior to intervention, 36 patients gave informed consent to participate in this study, which was approved by the Stanford University Institutional Review Board. Three patients declined to participate following randomization but before treatment initiation. In addition, 28 healthy control participants gave informed consent and participated in the same procedures as the depressed patients did pre-treatment (healthy participants were not re-assessed). A structured clinical interview was performed to assess depressive symptoms and other diagnoses. All depressed patients were 18–50-year-old, right handed, and met criteria for DSM-IV defined major depression . Depressed patients were either medication-free or were washed off of their medications for 2 weeks prior to therapy initiation. In order to limit placebo response rates that would diminish active-sham rTMS comparisons, but not enrich for an excessively treatment-resistant population , inclusion criteria included failure of one adequate antidepressant trial within-episode , but not > 3 failures.
After initial assessments and baseline resting fMRI, TMS/EEG, and TMS/fMRI, patients were randomized to active (N = 20) or sham (N = 13) rTMS treatment in a 2:1 ratio within a double-blind sham-controlled design (Fig. 1). See the CONSORT chart in Fig. S1 for further details.
Active rTMS treatment consisted of daily 10 Hz rTMS (4 s on, 26 s off) for 37.5 min (3000 pulses) for 4 consecutive weeks, and used neuronavigation to target the dlPFC node of the frontoparietal control network (FPCN; see Supplemental Methods). Sham rTMS was performed with a flipped TMS coil and electrical scalp stimulation to mimic rTMS.
Twenty-four hours after the last rTMS session, a post-treatment clinical assessment, resting fMRI, and TMS/EEG paradigms were performed to compare with pre-treatment.
Resting-state fMRI—functional connectivity analysis
All functional connectivity analyses were performed using standard tools in the CONN toolbox  (www.nitrc.org/projects/conn), after removing unwanted motion, physiological, and other artifactual effects from the BOLD signal as described in Supplemental Methods. We focused on connectivity from the target of TMS in the left dlPFC node of the FPCN, but as a control, we also calculated connectivity from ten other randomly selected prefrontal regions. We used linear mixed models to assess whether rTMS treatment, compared with sham, modulated connectivity from the site of stimulation, and whether connectivity values could predict clinical responses to treatment. Our connectivity metrics and statistical approaches are described in detail in Supplemental Methods.
To assess causal patterns of brain excitability before and after rTMS, we performed concurrent TMS/EEG mapping (N = 16 active rTMS, 12 sham rTMS, 28 total). EEG was recorded as single TMS pulses were applied to dlPFC nodes in the right and left frontoparietal control network (FPCN) and the left ventral attention network (VAN), as well as primary visual cortex (V1). Following artifact rejection, TMS-evoked potentials were quantified for each time window and electrode (see Supplemental Methods for further details). To compare the effects of treatment arm (active/sham rTMS) and time (pre/post-rTMS), we performed linear mixed model analysis within a full intent-to-treat framework to accommodate data loss or treatment dropout. In addition, we compared the effects of stimulation site and time using the same framework. For both analyses, a cluster-based non-parametric test was used to correct for multiple comparisons across evoked potential time windows and brain region.
To investigate normative patterns of downstream influence in brain regions identified by our resting fMRI analysis as demonstrating treatment-related change, a cohort of the depressed patients (N = 20) and a matched healthy cohort (N = 21) underwent a concurrent TMS/fMRI scanning session conducted according to established protocols . Single pulses were applied to either the FPCN or VAN left dlPFC nodes, and downstream fMRI BOLD responses were quantified and compared. See the Supplemental Methods section for further details.
Active rTMS led to a significant group reduction in depressive symptoms on the HamD (effect of time; F(1,33) = 26.4, p < 0.001). In each treatment arm, five patients were categorized as clinical responders (50% reduction in clinical symptoms; 5/18 or 27% in active rTMS, 5/13 or 38% in sham rTMS). Consistent with effect size expectations, given the sample size in our multimodal mechanism-focused design, this reduction did not significantly differ across treatment arms (treatment arm × time interaction: F(1,75) = 2.36, p = 0.135; HamDactive = 25.8 → 17.6; ΔHamDactive = −8.25; HamDsham = 25.9 → 15.1; ΔHamDsham = −10.83).
Resting fMRI connectivity
We first used a linear mixed model to test whether rTMS changed the global connectivity of the dlPFC stimulation site, i.e., the average connectivity of the stimulated voxels with the rest of the brain. Doing so revealed a significant treatment arm × time interaction (F(1,52) = 6.54, p = 0.013, Cohen’s d = 0.46, N = 31 Fig. 2a, b). This interaction was driven by a global connectivity increase with active rTMS (posthoc pairwise test, F(1,28) = 7.28, p = 0.012, Cohen’s d = 0.75, N = 18), but no change in connectivity in the sham arm (posthoc pairwise test, F(1,27) = 0.44, p = 0.51, Cohen’s d = 0.29, N = 13). These rTMS-induced connectivity changes brought patients closer, on average, to the connectivity patterns in healthy participants (Fig. 2b).
As a control for spatial specificity, we analyzed global connectivity from ten additional randomly -selected prefrontal seeds, which were not directly targeted by rTMS (Supplemental Fig. 2). When we combined the stimulation site with these ten additional seeds, we found a significant three-way interaction (seed × arm × time; F(43,420) = 2.16, p < 0.001), driven by the strong two-way interaction in the stimulation site. Indeed, when analyzed separately, there were no significant treatment arm × time interactions in any of the other regions (all p > 0.1).
To further understand rTMS-induced changes in dlPFC connectivity, we generated seeded connectivity maps from each patient’s site of stimulation, examining targets across cortico-limbic circuitry implicated in depression (i.e., lateral and medial PFC, insula, and amygdala) [29, 30]. This revealed significant connectivity changes in the bilateral amygdalae and contralateral dlPFC (Fig. 2c, Supplemental Tables 2 and 3, Supplemental Figs. 3 and 4). As above, these active rTMS-induced changes brought patients closer to controls (Fig. 2c; see pairwise statistics in the figure legend). Notably, the normative negative dlPFC-amygdala connectivity was evident only at post-treatment in the active rTMS arm.
We next determined how dlPFC global connectivity related to clinical treatment outcome. Within the active rTMS arm, baseline left dlPFC global connectivity predicted treatment outcome, such that patients with lower pre-treatment connectivity levels showed greater clinical improvement (linear mixed model, global connectivity × time interaction, F(1,31) = 8.52, p = 0.007, Cohen’s d = 1.59; illustrated with a median split in Fig. 2d). Moreover, pre-to-post increases in connectivity correlated negatively with pre-to-post HamD changes, indicating that active rTMS arm patients with the greatest increase in dlPFC global connectivity showed the greatest clinical improvement (r = –0.6, p = 0.01; Fig. 2e). By contrast, connectivity between the site of stimulation and the amygdalae and right dlPFC did not predict or track clinical outcome (prediction p’s > 0.42, tracking p’s > 0.23). Furthermore, within the sham rTMS arm, baseline left dlPFC global connectivity did not predict treatment outcome (F(1,22) = 0.40, p = 0.54, Cohen’s d = 1.21), and changes in connectivity did not correlate with changes in HamD score (r = −0.12, p = 0.72), although these results should be interpreted with caution given low power within the sham arm.
Next, we asked if there were differential effects of active vs. sham rTMS on the TMS-evoked potential (TEP), a tool to probe the causal neurophysiological influence of a brain region through single TMS pulses (Fig. 3a, b). After correcting for multiple comparisons across the TMS/EEG potentials examined, only the p30 (25–35 ms post-TMS pulse) demonstrated a significant treatment arm × time interaction in the linear mixed model analyses (Fig. 3c, d). Specifically, significant interaction effects were found separately in left frontal (linear mixed model, cluster-level statistic 38.06, p = 0.002, n = 5 electrodes) and parietal (cluster-level statistic 38.06, p = 0.002, n = 4 electrodes) electrodes for the p30 (Fig. 3d). These effects were driven by significant frontal and parietal p30 changes in the active but not sham rTMS arm (within-arm effect of time scalp significance topography plots in Fig. 3g and corresponding time series from significant treatment arm × time clusters in Fig. 3f). As shown in Fig. 3e, active but not sham rTMS reduced (and reversed) the p30 potential. Comparison with p30 responses in healthy individuals revealed that the change with active rTMS in patients was in the direction of normalization of p30 TEPs, similarly for both the frontal and parietal clusters. Finally, while baseline p30 responses in frontal or parietal clusters in active rTMS arm patients did not predict the magnitude of clinical change in linear mixed models, the amount of change in the prefrontal p30 responses with treatment did scale with symptom change. The greater the reduction in prefrontal p30 responses with active rTMS, the greater the associated clinical change (r = 0.72, p = 0.0025; Fig. 3h).
Finally, we evaluated the site-specificity of this p30 finding by comparing the change in p30 TEPs after active rTMS at the left FPCN dlPFC to changes at the right FPCN dlPFC, left VAN dlPFC, or V1 stimulation sites. We hypothesized that network changes induced by left FPCN dlPFC rTMS would most likely be observed following TMS/EEG to the treated network (left FPCN) and not other networks. We observed significant stimulation site × time interaction effects in the comparison between the treatment site and all other sites (see Fig. 4), suggesting that p30 suppression after active rTMS was observed only after single pulses to the treatment site. In summary, active rTMS suppressed the p30 potential, and greater rTMS-induced suppression correlated with better clinical outcome.
The results above imply that connectivity from the dlPFC to specific downstream regions might underlie the clinical effects of rTMS. Do these regions also show abnormalities in the causal influence of the dlPFC in depressed patients at baseline? To find out, we took advantage of concurrent TMS/fMRI, examining responses in the amygdalae and right dlPFC ROIs identified above following single TMS pulses to the left FPCN dlPFC site. We again used the nearby left VAN dlPFC site as a control for spatial specificity. A linear mixed model revealed a significant interaction between stimulation site (FPCN vs. VAN dlPFC) and group (healthy vs. depressed) (F = 7.50, p = 0.007), but no further interaction with ROI (amygdalae and right dlPFC), suggesting similar effects across ROIs. Indeed, testing for a stimulation site × group interaction separately for each ROI revealed a significant effect in the left amygdala (F(1,39) = 5.34, p = 0.026), right dlPFC (F(1,39) = 5.68, p = 0.022) and a trend in the right amygdala (F(1,39) = 3.47, p = 0.070). In healthy individuals, FPCN dlPFC stimulation led to negative fMRI responses (deactivation) in the amygdala and no change in the right dlPFC (Fig. 5a). By contrast, depressed patients failed to show amygdala deactivation and showed aberrant right dlPFC activation. None of these group differences were evident following left VAN dlPFC stimulation (Fig. 5b) despite the proximity to the stimulation site. In summary, concurrent TMS/fMRI demonstrates that stimulation of left FPCN dlPFC normally deactivates the amygdala, but depressed patients do not show this effect.
To better understand how rTMS treatment in depression modulates brain activity, we performed a randomized, sham-controlled, mechanism-focused clinical trial and measured electrophysiological, neuroimaging, and clinical changes before and after rTMS. Our findings were as follows: (1) Active but not sham rTMS increased dlPFC resting fMRI global connectivity and induced negative connectivity with bilateral amygdala that was not present at baseline, with global connectivity predicting and tracking the degree of clinical change; (2) Active but not sham rTMS suppressed the early TMS-evoked potential (potentially representing cortical inhibition, thus suggesting a post-rTMS reduction in intracortical inhibition), localized to left-sided prefrontal and parietal cortices, with the change in this signal tracking the degree of clinical change; and (3) Depressed patients failed to show healthy inhibition of amygdala activity from single TMS pulses to the dlPFC delivered during concurrent TMS/fMRI. Together, these results suggest that rTMS induces long-lasting neuromodulatory effects, characterized by a reduction of electrophysiological metrics thought to index local intracortical inhibition and a restoration of healthy negative dlPFC-amygdala connectivity. Important limitations to consider in the interpretation of these findings is the small sample (a common limitation of highly multimodal studies), the high placebo rate making it difficult to discern TMS-specific and non-specific factors, the lack of separation between active/sham treatment arms (although not powered for clinical separation), the fact that sham rTMS may have components that are not fully inert, the potential lack of generalizability to more complex clinical samples (e.g., rTMS and assessments performed in a laboratory context in medication-free patients rather than in a clinic context with concurrent medication use), the method of identifying the target TMS site (using normative resting fMRI maps with higher signal-to-noise as opposed to individualized maps with lower signal-to-noise), the fact that equipment failure precluded direct testing of the pre-specified ClinicalTrials.gov hypotheses, and remaining questions about the physiological mechanisms underlying TMS/EEG and fMRI signals.
Ten hertz rTMS may reduce prefrontal intracortical inhibition
While increased excitation through LTP is widely thought to underlie rTMS effects, our evidence suggests that rTMS may instead reduce prefrontal intracortical inhibition, leading to clinical improvement in depressive symptoms. Indeed, rTMS in animal experimental settings has been shown to decrease interneuron firing  and reduce the inhibitory notch commonly seen in visual evoked activity . We recently reported that 10 Hz prefrontal intracranial electrical stimulation in humans suppressed the intracranial p30 evoked response [19, 32]. These results are consistent with the TMS/EEG findings reported here, where active rTMS suppressed the p30 specifically in the stimulated network. Importantly, we observed changes specific to early potentials, stimulation site, and treatment arm, all of which controls for non-specific effects of TMS . While the neurophysiological mechanisms of other TMS/EEG potentials are clearer than for the p30, the reduction in the p30 may reflect a reduction in GABA-Aergic inhibition. Electrical stimulation in slices , pharmacological manipulation in humans , and paired -pulse human TMS experiments  have been linked to GABA-Aergic activity. Therefore, rTMS may elicit neural facilitation due to decreased prefrontal intracortical inhibition rather than through LTP. Future work replicating these findings in a larger sample and linking human p30 results to animal model and pharmacologic investigations are necessary to further elucidate this critical mechanistic question.
Changes in dlPFC-amygdala connectivity
Using resting fMRI to examine long-range changes in connectivity, we found that active but not sham rTMS increased global dlPFC connectivity. Associated with this global connectivity increase was an enhancement of dlPFC-amygdala negative connectivity. Thus, while our EEG findings may represent decreased local inhibition around the dlPFC, our resting fMRI findings may represent enhanced inhibition from the dlPFC to the amygdala. In other words, if these findings replicate in future larger studies, rTMS may strengthen the ability of the dlPFC to exert top-down control elsewhere in the brain, particularly in the amygdala.
Consistent with our resting fMRI results, we found that healthy controls showed greater left amygdala deactivation than depressed patients following single TMS pulses to left dlPFC. This lack of amygdala deactivation in patients may arise from several scenarios, including dysregulated dlPFC-amygdala coupling, higher baseline levels of amygdala activation not effectively decreased via dlPFC control, or a shift in control mechanisms such that the amygdala is causally influenced by a different region in patients relative to healthy controls. There may be other regions mediating this functional link, and it is possible that these mediating regions underlie the difference between patients and healthy controls.
Our findings are consistent with studies suggesting that dlPFC-amygdala connectivity is altered in MDD [35,36,37], and that rTMS normalizes connectivity patterns . We previously showed that rTMS decreases FPCN hyperconnectivity (which includes the dlPFC stimulation site) and induces stronger dlPFC-DMN-negative connectivity . As the prior study did not include a sham arm, it is difficult to disentangle the effect of rTMS from sham. Here, we found the major change distinguishing active from sham rTMS was in dlPFC-amygdala connectivity. Treatment enhanced negative connectivity between these two sites. Further sham-controlled studies will be needed to replicate this finding and explore its consequences for cognitive and emotional functioning. It is notable that we were unable to replicate previous studies, suggesting rTMS weakens connectivity between the dlPFC and subgenual cingulate .
Predicting and tracking clinical response to rTMS
Both our EEG-based p30 and fMRI-based global connectivity markers related to HamD change. Depressed patients with low-dlPFC resting global connectivity at baseline improved to a greater degree following rTMS than those with high-dlPFC connectivity. Furthermore, the greater the enhancement of fMRI global connectivity or p30 suppression, the greater the clinical improvement. It is worth noting that these relationships were driven by a small subset of patients who responded well to rTMS treatment. Interestingly, although baseline global connectivity predicted clinical response, baseline dlPFC-amygdala connectivity did not, suggesting that some of the clinical benefit might arise from enhancing connectivity with other regions. Additionally, the dissociation between the specific fMRI and TMS/EEG findings in the active rTMS arm, and the similar clinical results in both the active and sham rTMS arms, is noteworthy. This may reflect the lower sample size in the sham group (and thus less likely to demonstrate significant effects) or the specific neurophysiological effects of active rTMS that may not directly relate to clinical effects. Finally, this study was powered to detect a medium effect size for our primary group × time analyses on brain function. Thus, some analyses, particularly those of individual differences in brain-clinical benefit relationships, were less well-powered and should be interpreted with caution. Larger studies are needed to determine the external validity of these brain-symptoms relationships and to explore the neural basis of responders in the sham rTMS group. Future work with TMS/fMRI measurements before and after active vs. sham rTMS will also be necessary to address causal network abnormalities, as we had originally set out to do in our ClinicalTrials.gov registration.
In addition to addressing some of the domains in which current knowledge is lacking regarding how to best interpret resting fMRI and TMS/EEG findings, our results suggest that future work focusing on target engagement and dose–response in the manner pursued here, with the proper sham controls and multimodal measurements, could provide the mechanistic basis for second-generation personalized brain stimulation.
Funding and disclosure
AE was supported by a Dana Foundation grant and NIH grant DP1 MH116506. NE was supported by NIH T32 MH019908. CJK was supported by the NIH Early Independence Award DP5 OD028128, NIMH K23 MH11846601, the Stanford Society of Physician Scholars Collaborative Research Fellowship and the Alpha Omega Alpha Postgraduate Research Award. GAF was supported by NIMH grant T32 MH019938 and the Office of Academic Affiliations, Advanced Fellowship Program in Mental Illness Research and Treatment, Department of Veterans Affairs. AE holds equity at Mindstrong Health and Akili Interactive for unrelated work. The other authors have no financial disclosures. As of November 1, 2019 AE also received salary and equity from Alto Neuroscience. As of December 16, 2019 CJK received salary and equity from Alto Neuroscience. WW was supported in part by the National Natural Science Foundation of China (No. 61876063 and No. 61836003). The other authors have no financial disclosures.
The data that support the findings of this study are available on request from the corresponding author. The data are not publicly available because they contain information that could compromise the privacy of research participants.
Sinyor M, Schaffer A, Levitt A. The sequenced treatment alternatives to relieve depression (STAR*D) trial: a review. Can J Psychiatry. 2010;55:126–35.
Thase ME. The need for clinically relevant research on treatment-resistant depression. J Clin Psychiatry. 2001;62:221–4.
Noda Y, Silverstein WK, Barr MS, Vila-Rodriguez F, Downar J, Rajji TK, et al. Neurobiological mechanisms of repetitive transcranial magnetic stimulation of the dorsolateral prefrontal cortex in depression: a systematic review. Psychol Med. 2015;45:3411–32.
Berlim MT, van den Eynde F, Tovar-Perdomo S, Daskalakis ZJ. Response, remission and drop-out rates following high-frequency repetitive transcranial magnetic stimulation (rTMS) for treating major depression: a systematic review and meta-analysis of randomized, double-blind and sham-controlled trials. Psychol Med. 2014;44:225–39.
Fitzgerald PB, Hoy KE, Anderson RJ, Daskalakis ZJ. A study of the pattern of response to rTMS treatment in depression. Depress Anxiety. 2016;33:746–53.
George MS, Lisanby SH, Avery D, McDonald WM, Durkalski V, Pavlicova M, et al. Daily left prefrontal transcranial magnetic stimulation therapy for major depressive disorder: a sham-controlled randomized trial. Arch Gen Psychiatry. 2010;67:507–16.
O’Reardon JP, Solvason HB, Janicak PG, Sampson S, Isenberg KE, Nahas Z, et al. Efficacy and safety of transcranial magnetic stimulation in the acute treatment of major depression: a multisite randomized controlled trial. Biol Psychiatry. 2007;62:1208–16.
Glasser MF, Coalson TS, Robinson EC, Hacker CD, Harwell J, Yacoub E, et al. A multi-modal parcellation of human cerebral cortex. Nature. 2016;536:171–8.
Taylor SF, Ho SS, Abagis T, Angstadt M, Maixner DF, Welsh RC, et al. Changes in brain connectivity during a sham-controlled, transcranial magnetic stimulation trial for depression. J Affect Disord. 2018;232:143–51.
Siddiqi SH, Trapp NT, Hacker CD, Laumann TO, Kandala S, Hong X, et al. Repetitive transcranial magnetic stimulation with resting-state network targeting for treatment-resistant depression in traumatic brain injury: a randomized, controlled, double-blinded pilot study. J Neurotrauma. 2019;36:1361–74.
Ning L, Makris N, Camprodon JA, Rathi Y. Limits and reproducibility of resting-state functional MRI definition of DLPFC targets for neuromodulation. Brain Stimul. 2019;12:129–38.
Philip NS, Barredo J, Aiken E, Carpenter LL. Neuroimaging mechanisms of therapeutic transcranial magnetic stimulation for major depressive disorder. Biol Psychiatry Cogn Neurosci Neuroimaging. 2018;3:211–22.
Downar J, Geraci J, Salomons TV, Dunlop K, Wheeler S, McAndrews MP, et al. Anhedonia and reward-circuit connectivity distinguish nonresponders from responders to dorsomedial prefrontal repetitive transcranial magnetic stimulation in major depression. Biol Psychiatry. 2014;76:176–85.
Liston C, Chen AC, Zebley BD, Drysdale AT, Gordon R, Leuchter B, et al. Default mode network mechanisms of transcranial magnetic stimulation in depression. Biol Psychiatry. 2014;76:517–26.
Fox MD, Buckner RL, White MP, Greicius MD, Pascual-Leone A. Efficacy of transcranial magnetic stimulation targets for depression is related to intrinsic functional connectivity with the subgenual cingulate. Biol Psychiatry. 2012;72:595–603.
Speer AM, Kimbrell TA, Wassermann EM, D Repella J, Willis MW, Herscovitch P, et al. Opposite effects of high and low frequency rTMS on regional brain activity in depressed patients. Biol Psychiatry. 2000;48:1133–41.
Baeken C, De Raedt R, Van Schuerbeek P, Vanderhasselt MA, De Mey J, Bossuyt A, et al. Right prefrontal HF-rTMS attenuates right amygdala processing of negatively valenced emotional stimuli in healthy females. Behav Brain Res. 2010;214:450–5.
Kozyrev V, Eysel UT, Jancke D. Voltage-sensitive dye imaging of transcranial magnetic stimulation-induced intracortical dynamics. Proc Natl Acad Sci USA. 2014;111:13553–8.
Keller CJ, Huang Y, Herrero JL, Fini M, Du V, Lado FA, et al. Induction and quantification of excitability changes in human cortical networks. J Neurosci. 2018;38:5384–98.
Connors BW, Malenka RC, Silva LR. Two inhibitory postsynaptic potentials, and GABAA and GABAB receptor-mediated responses in neocortex of rat and cat. J Physiol. 1988;406:443–68.
Premoli I, Castellanos N, Rivolta D, Belardinelli P, Bajo R, Zipser C, et al. TMS-EEG signatures of GABAergic neurotransmission in the human cortex. J Neurosci. 2014;34:5603–12.
Kerwin LJ, Keller CJ, Wu W, Narayan M, Etkin A. Test-retest reliability of transcranial magnetic stimulation EEG evoked potentials. Brain Stimul 2018;11:536–44.
Wu W, Keller CJ, Rogasch NC, Longwell P, Shpigel E, Rolle CE, et al. ARTIST: a fully automated artifact rejection algorithm for single-pulse TMS-EEG data. Hum Brain Mapp. 2018;39:1607–25.
Chen AC, Oathes DJ, Chang C, Bradley T, Zhou ZW, Williams LM, et al. Causal interactions between fronto-parietal central executive and default-mode networks in humans. Proc Natl Acad Sci USA. 2013;110:19944–9.
First MB, Spitzer RL, Gibbon M, Williams JBW. Structured Clinical Interview for DSM-IV-TR Axis I Disorders, Research Version, Patient Edition. New York, NY: Biometrics Research, New York State Psychiatric Institute; 2002.
Lisanby SH, Husain MM, Rosenquist PB, Maixner D, Gutierrez R, Krystal A, et al. Daily left prefrontal repetitive transcranial magnetic stimulation in the acute treatment of major depression: clinical predictors of outcome in a multisite, randomized controlled clinical trial. Neuropsychopharmacol: Off Publ Am Coll Neuropsychopharmacol. 2009;34:522–34.
Prudic J, Haskett RF, Mulsant B, Malone KM, Pettinati HM, Stephens S, et al. Resistance to antidepressant medications and short-term clinical response to ECT. Am J psychiatry. 1996;153:985–92.
Whitfield-Gabrieli S, Nieto-Castanon A. Conn: a functional connectivity toolbox for correlated and anticorrelated brain networks. Brain Connect. 2012;2:125–41.
Dalgleish T. The emotional brain. Nat Rev Neurosci. 2004;5:583–9.
Fonzo GA, Goodkind MS, Oathes DJ, Zaiko YV, Harvey M, Peng KK, et al. Selective effects of psychotherapy on frontopolar cortical function in PTSD. Am J Psychiatry. 2017;174:1175–84.
Lenz M, Galanis C, Muller-Dahlhaus F, Opitz A, Wierenga CJ, Szabo G, et al. Repetitive magnetic stimulation induces plasticity of inhibitory synapses. Nat Commun. 2016;7:10020.
Huang Y, Hajnal B, Entz L, Fabo D, Herrero JL, Mehta AD, et al. Intracortical dynamics underlying repetitive stimulation predicts changes in network connectivity. J Neurosci. 2019;39:6122–35.
Conde V, Tomasevic L, Akopian I, Stanek K, Saturnino GB, Thielscher A, et al. The non-transcranial TMS-evoked potential is an inherent source of ambiguity in TMS-EEG studies. Neuroimage. 2018;185:300–12.
Cash RF, Noda Y, Zomorrodi R, Radhu N, Farzan F, Rajji TK, et al. Characterization of Glutamatergic and GABAA-mediated neurotransmission in motor and dorsolateral prefrontal cortex using paired-pulse TMS-EEG. Neuropsychopharmacology. 2017;42:502–11.
Dannlowski U, Ohrmann P, Konrad C, Domschke K, Bauer J, Kugel H, et al. Reduced amygdala-prefrontal coupling in major depression: association with MAOA genotype and illness severity. Int J Neuropsychopharmacol. 2009;12:11–22.
Erk S, Mikschl A, Stier S, Ciaramidaro A, Gapp V, Weber B, et al. Acute and sustained effects of cognitive emotion regulation in major depression. J Neurosci. 2010;30:15726–34.
Grant MM, White D, Hadley J, Hutcheson N, Shelton R, Sreenivasan K, et al. Early life trauma and directional brain connectivity within major depression. Hum Brain Mapp. 2014;35:4815–26.
Anderson RJ, Hoy KE, Daskalakis ZJ, Fitzgerald PB. Repetitive transcranial magnetic stimulation for treatment resistant depression: Re-establishing connections. Clin Neurophysiol 2016;127:3394–405.
Pizzagalli DA. Frontocingulate dysfunction in depression: toward biomarkers of treatment response. Neuropsychopharmacology. 2011;36:183–206.
We are enormously indebted to the patients who participated in this study. We thank Jillian Autea for clinical trial coordination.
Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Rights and permissions
About this article
Cite this article
Eshel, N., Keller, C.J., Wu, W. et al. Global connectivity and local excitability changes underlie antidepressant effects of repetitive transcranial magnetic stimulation. Neuropsychopharmacol. 45, 1018–1025 (2020). https://doi.org/10.1038/s41386-020-0633-z
This article is cited by
Functional connectivity changes between amygdala and prefrontal cortex after ECT are associated with improvement in distinct depressive symptoms
European Archives of Psychiatry and Clinical Neuroscience (2023)
Noninvasive neuromodulation of the prefrontal cortex in mental health disorders
Connectome-guided transcranial magnetic stimulation treatment in depression
European Child & Adolescent Psychiatry (2022)